Fubotv earnings beat by $0.10, revenue topped estimates
SEATTLE - Sana Biotechnology, Inc. (NASDAQ:SANA), whose stock has surged over 160% year-to-date according to InvestingPro data, announced Wednesday it has commenced an underwritten public offering of $75 million of its common stock and pre-funded warrants to purchase common shares for certain investors.
The biotechnology company, which focuses on engineered cell therapies and currently maintains a market capitalization of approximately $956 million, also plans to grant underwriters a 30-day option to purchase up to an additional $11.25 million of common shares. All securities in the proposed offering will be sold by Sana.
Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are serving as joint book-running managers for the offering, which is subject to market conditions and regulatory approvals.
The company noted in its press release statement that there is no guarantee regarding the completion, timing, or final terms of the proposed offering.
Sana Biotechnology, which operates facilities in Seattle, Cambridge, and South San Francisco, is offering the securities pursuant to a previously filed and effective Registration Statement on Form S-3 with the Securities and Exchange Commission.
The company describes itself as focused on "creating and delivering engineered cells as medicines for patients," according to the announcement.
The offering comes as biotechnology companies continue to seek capital to fund research and development activities. Sana has not specified the intended use of proceeds from the offering in the press release.
In other recent news, Sana Biotechnology reported promising six-month follow-up results from a first-in-human study of its cell therapy for type 1 diabetes. The company’s UP421 allogeneic primary islet cell therapy, engineered with hypoimmune technology, demonstrated survival and function of pancreatic beta cells without requiring immunosuppression. This study, conducted in partnership with Uppsala University Hospital, showed the presence of circulating C-peptide, a biomarker of insulin production, and increased levels during a mixed meal tolerance test, indicating insulin secretion in response to food intake. These developments have sparked interest in the company’s innovative approach to diabetes treatment.
Additionally, Morgan Stanley has initiated coverage on Sana Biotechnology with an Overweight rating and a $12.00 price target. The firm believes that Sana’s platform has the potential to develop differentiated therapies based on engineered cells. These recent developments highlight Sana’s ongoing efforts to advance its therapeutic offerings and capture the attention of the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.